Oltman C L, Weintraub N L, VanRollins M, Dellsperger K C
Department of Internal Medicine, University of Iowa, Iowa City, Iowa, USA.
Circ Res. 1998 Nov 2;83(9):932-9. doi: 10.1161/01.res.83.9.932.
Cytochrome P450 epoxygenases convert arachidonic acid into 4 epoxyeicosatrienoic acid (EET) regioisomers, which were recently identified as endothelium-derived hyperpolarizing factors in coronary blood vessels. Both EETs and their dihydroxyeicosatrienoic acid (DHET) metabolites have been shown to relax conduit coronary arteries at micromolar concentrations, whereas the plasma concentrations of EETs are in the nanomolar range. However, the effects of EETs and DHETs on coronary resistance arterioles have not been examined. We administered EETs and DHETs to isolated canine coronary arterioles (diameter, 90.0+/-3.4 microm; distending pressure, 20 mm Hg) preconstricted by 30% to 60% of the resting diameter with endothelin. All 4 EET regioisomers produced potent, concentration-dependent vasodilation (EC50 values ranging from -12.7 to -10.1 log [M]) and were approximately 1000 times more potent than reported in conduit coronary arteries. The vasodilation produced by 14,15-EET was not attenuated by removal of the endothelium and indicated a direct action of 14,15-EET on microvascular smooth muscle. Likewise, 14,15-DHET, 11,12-DHET, 8,9-DHET, and the delta-lactone of 5,6-EET produced extremely potent vasodilation (EC50 values ranging from -15.8 to -13.1 log [M]). The vasodilation produced by these eicosanoids was highly potent in comparison to that produced by other vasodilators, including arachidonic acid (EC50=-7.5 log [M]). The epoxide hydrolase inhibitor, 4-phenylchalone oxide, which blocked the conversion of [3H]14,15-EET to [3H]14,15-DHET by canine coronary arteries, did not alter arteriolar dilation to 11,12-EET; thus, the potent vasodilation induced by EETs does not require formation of DHETs. In contrast, charybdotoxin (a KCa channel inhibitor) and KCl (a depolarizing agent) blocked vasodilation by 11,12-EET and 11,12-DHET. We conclude that EETs and DHETs potently dilate canine coronary arterioles via activation of KCa channels. The preferential ability of these compounds to dilate resistance blood vessels suggests that they may be important regulators of coronary circulation.
细胞色素P450环氧合酶将花生四烯酸转化为4种环氧二十碳三烯酸(EET)区域异构体,最近它们被确定为冠状动脉中的内皮衍生超极化因子。EET及其二羟基二十碳三烯酸(DHET)代谢产物在微摩尔浓度下均可使冠状动脉主干舒张,而EET的血浆浓度处于纳摩尔范围。然而,EET和DHET对冠状动脉阻力小动脉的影响尚未得到研究。我们将EET和DHET应用于分离的犬冠状动脉小动脉(直径90.0±3.4微米;扩张压力20毫米汞柱),这些小动脉预先用内皮素收缩至静息直径的30%至60%。所有4种EET区域异构体均产生强效的、浓度依赖性的血管舒张作用(EC50值范围为-12.7至-10.1对数[M]),其效力比冠状动脉主干中报道的约强1000倍。14,15-EET产生的血管舒张作用不会因去除内皮而减弱,表明14,15-EET对微血管平滑肌有直接作用。同样,14,15-DHET、11,12-DHET、8,9-DHET和5,6-EET的δ-内酯也产生极强的血管舒张作用(EC50值范围为-15.8至-13.1对数[M])。与包括花生四烯酸(EC50=-7.5对数[M])在内的其他血管舒张剂相比,这些类花生酸产生的血管舒张作用非常强效。环氧水解酶抑制剂4-苯基查耳酮氧化物可阻断犬冠状动脉将[3H]14,15-EET转化为[3H]14,15-DHET,但不会改变小动脉对11,12-EET的舒张作用;因此,EET诱导的强效血管舒张作用不需要形成DHET。相反,蝎毒素(一种钾钙通道抑制剂)和氯化钾(一种去极化剂)可阻断11,12-EET和11,12-DHET引起的血管舒张。我们得出结论,EET和DHET通过激活钾钙通道使犬冠状动脉小动脉强效舒张。这些化合物优先舒张阻力血管的能力表明它们可能是冠状动脉循环的重要调节因子。